These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27538694)

  • 1. Cubosomes as Carriers for MRI Contrast Agents.
    Alcaraz N; Boyd BJ
    Curr Med Chem; 2017; 24(5):470-482. PubMed ID: 27538694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases.
    Zabara A; Mezzenga R
    J Control Release; 2014 Aug; 188():31-43. PubMed ID: 24910192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphiphilic brush polymers produced using the RAFT polymerisation method stabilise and reduce the cell cytotoxicity of lipid lyotropic liquid crystalline nanoparticles.
    Zhai J; Suryadinata R; Luan B; Tran N; Hinton TM; Ratcliffe J; Hao X; Drummond CJ
    Faraday Discuss; 2016 Oct; 191():545-563. PubMed ID: 27453499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cubic and hexagonal liquid crystals as drug delivery systems.
    Chen Y; Ma P; Gui S
    Biomed Res Int; 2014; 2014():815981. PubMed ID: 24995330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell interactions with lipid nanoparticles possessing different internal nanostructures: Liposomes, bicontinuous cubosomes, hexosomes, and discontinuous micellar cubosomes.
    Yap SL; Yu H; Li S; Drummond CJ; Conn CE; Tran N
    J Colloid Interface Sci; 2024 Feb; 656():409-423. PubMed ID: 38000253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured cubosomes as advanced drug delivery system.
    Pan X; Han K; Peng X; Yang Z; Qin L; Zhu C; Huang X; Shi X; Dian L; Lu M; Wu C
    Curr Pharm Des; 2013; 19(35):6290-7. PubMed ID: 23470001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cubosomes as an emerging platform for drug delivery: a review of the state of the art.
    Abourehab MAS; Ansari MJ; Singh A; Hassan A; Abdelgawad MA; Shrivastav P; Abualsoud BM; Amaral LS; Pramanik S
    J Mater Chem B; 2022 Apr; 10(15):2781-2819. PubMed ID: 35315858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymer Cubosomes: Infinite Cubic Mazes and Possibilities.
    Ha S; La Y; Kim KT
    Acc Chem Res; 2020 Mar; 53(3):620-631. PubMed ID: 31920073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Lamellar Lyotropic Liquid Crystalline Lipid Nanoparticles for the Next Generation of Nanomedicine.
    Zhai J; Fong C; Tran N; Drummond CJ
    ACS Nano; 2019 Jun; 13(6):6178-6206. PubMed ID: 31082192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-PEG conjugates sterically stabilize and reduce the toxicity of phytantriol-based lyotropic liquid crystalline nanoparticles.
    Zhai J; Hinton TM; Waddington LJ; Fong C; Tran N; Mulet X; Drummond CJ; Muir BW
    Langmuir; 2015 Oct; 31(39):10871-80. PubMed ID: 26362479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in the study of lipid-based cubic liquid crystalline nanoparticles as drug delivery system].
    Wu HB; Huo DF; Jiang XG
    Yao Xue Xue Bao; 2008 May; 43(5):450-5. PubMed ID: 18717329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cubosomes as versatile lipid nanocarriers for neurological disorder therapeutics: a comprehensive review.
    A Vahab S; Nair A; Raj D; G P A; P P S; S Kumar V
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3729-3746. PubMed ID: 38095651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.
    Nguyen TH; Hanley T; Porter CJ; Boyd BJ
    J Control Release; 2011 Jul; 153(2):180-6. PubMed ID: 21497623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging.
    Mulder WJ; Strijkers GJ; van Tilborg GA; Griffioen AW; Nicolay K
    NMR Biomed; 2006 Feb; 19(1):142-64. PubMed ID: 16450332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of Lipidic Cubic Phase Nanoparticles with Lipid Membranes.
    Jabłonowska E; Nazaruk E; Matyszewska D; Speziale C; Mezzenga R; Landau EM; Bilewicz R
    Langmuir; 2016 Sep; 32(37):9640-8. PubMed ID: 27550742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Size and phase control of cubic lyotropic liquid crystal nanoparticles.
    Hartnett TE; Ladewig K; O'Connor AJ; Hartley PG; McLean KM
    J Phys Chem B; 2014 Jul; 118(26):7430-9. PubMed ID: 24915497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins.
    Rizwan SB; Boyd BJ; Rades T; Hook S
    Expert Opin Drug Deliv; 2010 Oct; 7(10):1133-44. PubMed ID: 20858165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
    Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
    Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the blood-brain barrier.
    Azhari H; Strauss M; Hook S; Boyd BJ; Rizwan SB
    Eur J Pharm Biopharm; 2016 Jul; 104():148-55. PubMed ID: 27163239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent patents on nonlamellar liquid crystalline lipid phases in drug delivery.
    Koynova R; Tenchov B
    Recent Pat Drug Deliv Formul; 2013 Dec; 7(3):165-73. PubMed ID: 23829393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.